JNJ 64400141

Drug Profile

JNJ 64400141

Alternative Names: Ad26.RSV.preF; JNJ-64400141

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 10 Nov 2017 Janssen plans a phase II trial for Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in USA (IM) (NCT03339713)
  • 16 Oct 2017 Phase-II clinical trials in Respiratory syncytial virus infections (Prevention, In adults) in United Kingdom (IM) (NCT03334695)
  • 09 Oct 2017 Janssen plans a phase I/II trial in Healthy volunteers (In infants, In children, In adolescents, In adults) in United Kingdom (NCT03303625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top